Barriers to hepatitis C direct‐acting antiviral therapy among HIV/hepatitis C virus‐coinfected persons. Issue 4 (8th September 2020)

• Record Type: Journal Article
• Authors: Jatt, Lauren P.; Gandhi, Malini M.; Guo, Rong; Sukhija‐Cohen, Adam; Bhattacharya, Debika; Tseng, Chi‐hong; Chew, Kara W.
• Other Names: Yu Jun guestEditor.
• Is Part Of: Journal of gastroenterology and hepatology. Volume 36:Issue 4(2021)
• Page Start: 1095
• Page End: 1102
• Publication Date: 2020-09-08
• Subjects: Access to care -- AIDS/HIV -- Antiretroviral therapy -- Direct‐acting antiviral (DAA) therapy -- Disparities -- HCV treatment -- Substance use; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.15228
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background and Aim: Direct‐acting antivirals (DAAs) have increased hepatitis C virus (HCV) treatment opportunities for vulnerable HIV/HCV coinfected persons. The aim of this study was to identify the frequency of and potential barriers to DAA prescription in HIV/HCV patients during the first few years of DAA availability in the United States. Methods: The AIDS Healthcare Foundation electronic medical record system was queried to identify all HCV viremic HIV‐infected patients in care at AIDS Healthcare Foundation Healthcare centers in January 2015–August 2017 and compare characteristics by receipt of a DAA prescription. Multivariate logistic regression analyses were conducted to examine factors associated with DAA prescription. Results: Of 826 eligible patients, 355 (43%) were prescribed a DAA; among those not prescribed a DAA, 301 (64%) had well‐controlled HIV (HIV RNA ≤ 200 copies per mL). In multivariate logistic regression analysis, patients with a history of substance use (odds ratio [OR], 0.51 [95% confidence interval 0.35–0.73]) or on select HIV antiretroviral regimens were less likely to be prescribed a DAA. Those who had well‐controlled HIV (OR, 5.03 [3.06–8.27]), CD4 + T cell count >200 cells per mm 3 (OR, 1.85 [1.04–3.30]), estimated glomerular filtration rate >60 mL/min/1.73 m 2 (OR, 3.32 [1.08–10.15]), or established care prior to January 2015 (OR, 1.57 [1.08–2.29] were more likely to be prescribed a DAA. Conclusions: In addition to lack of HIV suppression, select antiretroviral regimens, substance use, and kidney disease appeared to limit DAA prescription in the early interferon‐free DAA era. Many were not prescribed DAAs despite HIV suppression. Further research is needed to determine if the observed associations persist today.